Abstract: Provided is a thermal molding method for producing a thermally molded article having excellent abrasion resistance at its melt-fused part. Polyamide 6 and a copolyester are prepared separately. The copolyester contains terephthalic acid, ethylene glycol, and 1,4-butanediol as copolymerization units. The copolyester may further contain ?-caprolactone and/or diethylene glycol as a copolymerization unit. A multifilament yarn in which core-sheath type composite filaments each containing a core component and a sheath component at a ratio of 1 to 4:1 by mass are bundled is produced by a composite melt-spinning method using the polyamide 6 as the core component and the copolyester as the sheath component. Using the multifilament yarn, a product of filaments is produced by weaving, knitting, knitting and braiding, or braiding.

Abstract: The present invention relates to a composition comprising: (a) at least one particle comprising at least one cationic polymer and at least one anionic polymer, at least one cationic polymer and at least one amphoteric polymer, at least one anionic polymer and at least one amphoteric polymer, or at least one amphoteric polymer, and at least one non-polymeric acid having two or more pKa values or salt(s) thereof or at least one non-polymeric base having two or more pKb values or salt(s) thereof; (b) at least one surfactant; and (c) water, wherein the anionic polymer is selected from hyaluronic acid and derivatives thereof, and the amphoteric polymer is selected from cationized hyaluronic acid and salts thereof. The composition according to the present invention can provide long lasting cosmetic effects and/or improved moisturizing texture based on hyaluronic acid or cationized hyaluronic acid.

Abstract: In one embodiment, the object of the present invention is to provide a nephrotoxicity reducing agent for a pharmaceutical composition comprising an antisense oligomer, and a method for reducing nephrotoxicity of the pharmaceutical composition. In one embodiment, the present invention relates to a nephrotoxicity reducing agent for a pharmaceutical composition comprising an antisense oligomer, wherein the nephrotoxicity reducing agent comprises a sugar alcohol and is used in an amount such that the concentration of the sugar alcohol in the pharmaceutical composition is 1 mg/ml to 400 mg/mL.

Abstract: Cultured cells flat-cultured on a permeable sheet is stacked on other flat-cultured cells together with the permeable sheet to construct a three-dimensional tissue. The three-dimensional tissue is transplanted into a living body. Alternatively, the three-dimensional tissue is stacked up in an artificial organ device to construct a stacked-up, three-dimensional bioartificial organ module. Colony form of the cultured cell can be controlled by using a microporous sheet as the permeable sheet and controlling positions of pores in the microporous sheet to design the form of the artificial organ.